Nemus Bioscience, Inc. Changes Name to Emerald Bioscience, Inc. and Provides Update of Recent Research Accomplishments
March 25, 2019 08:00 ET
|
Emerald Bioscience, Inc.
Name Change Reflects Company’s Focus on Advancing Cannabinoid-Based Therapeutics as a Member of the Emerald Group Company to Trade on OTCQB Under Ticker EMBI at Market Open March 25, 2019 ...
Nemus Bioscience to Present at 31st Annual ROTH Conference
March 13, 2019 07:36 ET
|
Nemus Bioscience, Inc.
Long Beach, CA, March 13, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nemus Bioscience, Inc. (OTCQB: NMUS), a biopharmaceutical company focused on bioengineered cannabinoid-based therapeutics to...
Nemus Bioscience Confirms NB1111 Mechanism of Action and Reports Positive Results from Glaucoma Biomarker Studies in Human Donor Tissues
March 12, 2019 07:30 ET
|
Nemus Bioscience, Inc.
Prodrug of THC Improves Fluid Outflow Across Trabecular Meshwork and Positively Impacts Disease Markers Associated with Glaucoma-Related Fibrosis and Inflammation Changes in Neovascularization...
Nemus Bioscience Signs Agreement with Noramco to Manufacture Proprietary Cannabidiol Analog
March 04, 2019 07:30 ET
|
Nemus Bioscience, Inc.
Enhanced Bioavailability Could Prove Pivotal in Providing Neuroprotection in Diseases of the Retina LONG BEACH, CA, March 04, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Nemus Bioscience, Inc....
Nemus Bioscience to Present at BIO Investor Forum
October 15, 2018 08:30 ET
|
Nemus Bioscience, Inc.
LONG BEACH, CA, Oct. 15, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Nemus Bioscience, Inc. (OTCQB: NMUS), focused on the development of cannabinoid-based therapeutics to address global medical...
Nemus Bioscience Announces that Emerald Health Sciences has Provided a Credit Facility of up to $20 Million and Adopted an Open Market Share Purchase Program of up to 10 Million Common Shares
October 08, 2018 08:00 ET
|
Nemus Bioscience, Inc.
Avtar Dhillon, MD, appointed as Executive Chairman of Nemus LONG BEACH, CA, Oct. 08, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Nemus Bioscience, Inc. (OTCQB: NMUS), focused on the...
NEMUS Bioscience to Present at The MicroCap Conference
September 26, 2018 08:00 ET
|
Nemus Bioscience, Inc.
LONG BEACH, CA, Sept. 26, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE - NEMUS Bioscience, Inc. (OTCQB: NMUS), focused on the development of cannabinoid-based therapeutics to address global medical...
UPDATE: Nemus Bioscience, Inc. Signs Agreement with Albany Molecular Research Inc. (AMRI) to Manufacture Cannabinoid-Based Active Pharmaceutical Ingredient for Glaucoma
August 01, 2018 09:54 ET
|
Nemus Bioscience, Inc.
Long Beach, CA, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Nemus Bioscience, Inc. (OTCQB: NMUS), focused on the development of cannabinoid-based therapeutics to address global medical indications, especially...
Prominent Salk Institute Neuroscientist Joins Nemus Bioscience as Scientific Consultant
March 21, 2018 08:30 ET
|
Nemus Bioscience, Inc.
Dr. David Schubert to advise Nemus on neuroprotection and CNS applications of the company’s proprietary cannabinoid portfolio COSTA MESA, CA. , March 21, 2018 (GLOBE NEWSWIRE) -- Nemus...
Nemus Secures Emerald Health as Strategic Majority Investor to help Advance Clinical Development of Novel Cannabinoid-based Therapeutics
January 19, 2018 08:30 ET
|
Nemus Bioscience, Inc.
Nemus Bioscience Receives $400,000 Funding under Convertible Bridge Loan and Closes Initial $1,500,000 Private Placement COSTA MESA, Calif., Jan. 19, 2018 (GLOBE NEWSWIRE) -- NEMUS Bioscience, Inc....